Skip to content

Evidence of effective adherence interventions is still limited

Adherence data needs to be collected in real time, before the damage is done

Once-a-day treatment: the consequences of poor adherence may be more serious

Six existing drug classes now being tested as microbicides

Even with antiretroviral treatment, patients with HIV still have markers indicating increased risk of heart disease and kidney problems

New grants for HIV cure research

Avexa halts apricitabine development due to cash shortage

Majority of HIV patients in North America need to start treatment at time of diagnosis

Huge variations in price paid for same antiretroviral drug between low-income countries